Unresectable Breast Cancer research hub

DESTINY Breast Respond HER2-low Europe

This study looks at a medicine called Trastuzumab deruxtecan (T-DXd) for advanced breast cancer that's HER2-low. It aims to understand how patients use it in real life, how well it works, and if they have any side effects, along with other chemotherapy options.